albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-25. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The liver is found in all vertebrates and is typically the largest internal organ. The internal structure of the liver is broadly similar in all vertebrates, though its form varies considerably in different species, and is largely determined by the shape and arrangement of the surrounding organs. Nonetheless, in most species, it is divided into right and left lobes; exceptions to this general rule include snakes, where the shape of the body necessitates a simple cigar-like form. In neonatal marsupials, it is responsible for the production of blood cells. An organ sometimes referred to as a liver is found associated with the digestive tract of the primitive chordate amphioxus. Although it performs many functions of a liver, it is not considered a "true" liver but rather a homolog of the vertebrate liver. The amphioxus hepatic caecum produces the liver-specific proteins vitellogenin, antithrombin, plasminogen, alanine aminotransferase, and insulin/insulin-like growth factor.
This is a list of the fastest animals in the world, by types of animal. The peregrine falcon is the fastest bird, and the fastest member of the animal kingdom, with a diving speed of over 300 km/h (190 mph). The fastest land animal is the cheetah, capable of running at speeds of up to 93–104 km/h (58–65 mph). Among the fastest animals in the sea is the black marlin, with uncertain and conflicting reports of recorded speeds. When drawing comparisons between different classes of animals, an alternative unit is sometimes used for organisms: body length per second. On this basis the 'fastest' organism on earth, relative to its body length, is the Southern Californian mite, Paratarsotomus macropalpis, which has a speed of 322 body lengths per second. The equivalent speed for a human, running as fast as this mite, would be 1,300 mph (2,092 km/h), or approximately Mach 1.7. The speed of the P. macropalpis is far in excess of the previous record holder, the Australian tiger beetle Rivacindela eburneola, which is the fastest insect in the world relative to body size, with a recorded speed of 1.86 metres per second (6.7 km/h; 4.2 mph), or 171 body lengths per second. The cheetah, the fastest land mammal, scores at only 16 body lengths per second. Body mass can also be used to compare speed between species on a relative basis. Under this parameter the fastest animal for its body mass is the cheetah, followed by the pronghorn.
A compromise solution was worked out whereas the infantry would attack north from both sides of Lake Ilmen, while the panzer group would advance from its current position. Hoepner's forces began their advance on August 8, but the attack ran into determined Soviet defences. Elsewhere, Soviet counter-attacks threatened Leeb's southern flank. By mid to late August, the German forces were making gains again, with the 4th Panzer Group taking Narva on 17 August. On 29 August, Leeb issued orders for the blockade of Leningrad in anticipation that the city would soon be abandoned by the Soviets. On September 5, Hitler ordered Hoepner's 4th Panzer Group and an air corps transferred to Army Group Centre effective 15 September, in preparation for Operation Typhoon, the German assault on Moscow. Leeb objected and was given a reprieve in the transfer of his mobile forces, with the view of making one last push towards Leningrad. The 4th Panzer Group was to be the main attacking force, which reached south of the Neva River, where it was faced with strong Soviet counter-attacks. By 24 September, Army Group North halted its advance and transferred the 4th Panzer Group to Army Group Centre.
Sources: en.wikipedia.org
Hypermobility, also known as double-jointedness, describes joints that stretch farther than normal. For example, some hypermobile people can bend their thumbs backwards to their wrists, bend their knee joints backwards, put their leg behind the head, or perform other contortionist "tricks". It can affect one or more joints throughout the body. Hypermobile joints are common and occur in about 10 to 25% of the population. Most have no other issues. In a minority of people, pain and other symptoms are present. In some cases, hypermobile joints are a feature of connective tissue disorders. One of these, Ehlers-Danlos Syndrome, was classified into several types which have been found to be genetic. Hypermobile Ehlers–Danlos syndrome (hEDS), formerly called EDS Type 3, remains the only EDS variant without a diagnostic DNA test. In 2016 the diagnostic criteria for hEDS were re-written to be more restrictive, with the intent of narrowing the pool of hEDS patients, in the hope of making it easier to identify a common genetic mutation and create a diagnostic DNA test. At the same time, joint hypermobility syndrome was renamed as hypermobility spectrum disorder, and redefined as a hypermobility disorder that does not meet the diagnostic criteria for any heritable Connective Tissue Disorder (such as hEDS, other types of Ehlers–Danlos Syndrome, Marfan Syndrome, Loeys–Dietz Syndrome, or osteogenesis imperfecta).
=== Cholesterol biosynthesis === Cholesterol can be made from acetyl-CoA through a multiple-step pathway known as isoprenoid pathway. Cholesterol is an essential compound because it is a precursor for sex hormones, such as progesterone. 70% of cholesterol biosynthesis occurs in the cytosol of liver cells.
Duffy announced later that year that work would begin in 2027 and would cost $7 billion, and in May 2026 Amtrak selected out of three finalists a joint venture of Skanska and Halmar International as developer and Vishaan Chakrabarti's Practice for Architecture and Urbanism (PAU) as lead design architect. The approved plan would keep Madison Square Garden in place and rebuild the passenger facilities beneath it. In June 2026, Amtrak and Penn Transformation Partners released renderings for an approximately $8 billion redesign of Penn Station that would retain Madison Square Garden while creating a larger, light-filled station inspired by the original Pennsylvania Station. Later that month, a pre-development agreement (PDA) was finalized, with the project estimated to break ground by the end of 2027. Amtrak also offered to re-add the MTA as a partner in the station's reconstruction, but the MTA declined.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.